Original Research and the Latest News

How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%

Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success (POS) forecasting can revolutionize the landscape of clinical trials. By adopting next-gen POS forecasting models, companies can...

Not Your Grandparents’ Probability of Success Forecasts

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Who’s Winning the Pharmaceutical R&D Pipeline Race in 2025

The leaders, the contenders, and the strategies for success As we approach the 4th quarter of 2025, let’s review where the pharmaceutical industry’s leading companies rank in terms of overall pipeline strength.Roche, AstraZeneca, and Bristol-Myers Squibb sit in a...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Recent Posts

Recent Tweets

$SRRK +nan% today

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

More Info: https://pryzm.ozmosi.com/product/21745

$MIST +1.94% today

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

More Info: https://pryzm.ozmosi.com/product/825

$DTIL +nan% today

iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium

More Info: https://pryzm.ozmosi.com/product/27435

$NUVB -4.41% today

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

More Info: https://pryzm.ozmosi.com/product/22745

Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

600 Warren Ave,
Spring Lake, NJ 07762